CN114127061A - (r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺酰基)-1-氟乙基)-n-(异噁唑-3-基)哌啶-1-甲酰胺的多晶型物形式 - Google Patents

(r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺酰基)-1-氟乙基)-n-(异噁唑-3-基)哌啶-1-甲酰胺的多晶型物形式 Download PDF

Info

Publication number
CN114127061A
CN114127061A CN202080051794.8A CN202080051794A CN114127061A CN 114127061 A CN114127061 A CN 114127061A CN 202080051794 A CN202080051794 A CN 202080051794A CN 114127061 A CN114127061 A CN 114127061A
Authority
CN
China
Prior art keywords
polymorph
degrees
composition
composition according
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080051794.8A
Other languages
English (en)
Chinese (zh)
Inventor
钟民
O·蒙尼尔
J-P·杰林
R·迪沃克斯
J·艾丽
P·奥克辛本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myokardia Inc
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of CN114127061A publication Critical patent/CN114127061A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080051794.8A 2019-07-16 2020-07-15 (r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺酰基)-1-氟乙基)-n-(异噁唑-3-基)哌啶-1-甲酰胺的多晶型物形式 Pending CN114127061A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874855P 2019-07-16 2019-07-16
US62/874,855 2019-07-16
PCT/US2020/042028 WO2021011586A1 (en) 2019-07-16 2020-07-15 Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide

Publications (1)

Publication Number Publication Date
CN114127061A true CN114127061A (zh) 2022-03-01

Family

ID=71895284

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080051794.8A Pending CN114127061A (zh) 2019-07-16 2020-07-15 (r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺酰基)-1-氟乙基)-n-(异噁唑-3-基)哌啶-1-甲酰胺的多晶型物形式

Country Status (14)

Country Link
US (2) US20210053939A1 (https=)
EP (1) EP3999504A1 (https=)
JP (2) JP2022540678A (https=)
KR (1) KR20220035176A (https=)
CN (1) CN114127061A (https=)
AU (1) AU2020315605A1 (https=)
BR (1) BR112022000474A2 (https=)
CA (1) CA3143965A1 (https=)
CL (1) CL2022000050A1 (https=)
CO (1) CO2022000117A2 (https=)
IL (1) IL289817A (https=)
MX (1) MX2022000606A (https=)
PE (1) PE20220645A1 (https=)
WO (1) WO2021011586A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116082326A (zh) * 2022-12-16 2023-05-09 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
CN117865941A (zh) * 2024-03-13 2024-04-12 上海方予健康医药科技有限公司 取代哌啶化合物及其制备方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025244956A1 (en) 2024-05-20 2025-11-27 MyoKardia, Inc. Methods of manufacturing danicamtiv

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US20050250789A1 (en) 2004-04-20 2005-11-10 Burns David M Hydroxamic acid derivatives as metalloprotease inhibitors
ES2522579T3 (es) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
NZ590148A (en) 2004-12-30 2012-04-27 Janssen Pharmaceutica Nv Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
EP1866285A1 (en) 2005-03-03 2007-12-19 F. Hoffmann-Roche AG 1-sulfonyl-piperdine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus
WO2008120759A1 (ja) 2007-03-30 2008-10-09 Japan Tobacco Inc. ウレア化合物およびその用途
RU2462454C2 (ru) 2007-06-20 2012-09-27 Мицубиси Танабе Фарма Корпорейшн Новое сульфонамидное производное малоновой кислоты и его фармацевтическое применение
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
BRPI0817211A2 (pt) 2007-09-20 2017-05-16 Irm Llc composto composições como moduladores da atividade de gpr119
RU2010116821A (ru) 2007-10-01 2011-11-10 Ф.Хоффманн-Ля Аг (Ch) N-гетероциклические биарильные карбоксамиды в качестве антагонистов рецептора ccr
RU2487127C2 (ru) 2007-10-09 2013-07-10 Ф.Хоффманн-Ля Рош Аг Хиральные цис-имидазолины
NZ600238A (en) 2008-06-19 2014-04-30 Takeda Pharmaceutical Heterocyclic compound and use thereof
US8324178B2 (en) 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
WO2010113377A1 (ja) 2009-04-01 2010-10-07 パナソニック株式会社 デジタル周波数／位相ロックドループ
TWI472331B (zh) 2009-11-11 2015-02-11 Sumitomo Dainippon Pharma Co Ltd ８－氮雙環〔３‧２‧１〕辛烷－８－羧醯胺衍生物
US9771357B2 (en) 2013-07-09 2017-09-26 Ono Pharmaceutical Co., Ltd. ALXR agonist compound
KR102249564B1 (ko) 2013-08-07 2021-05-07 메르크 파텐트 게엠베하 피페리딘 우레아 유도체
ES2933350T3 (es) 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
EP4234017B1 (en) * 2015-01-22 2026-04-15 MyoKardia, Inc. Preparation of 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
KR20220009440A (ko) 2019-05-19 2022-01-24 미요카디아, 인크. 화합물 (r)-4-(1-((3-(디플루오로메틸)-1-메틸-1h-피라졸-4-일)술포닐)-1-플루오로에틸)-n-(이속사졸-3-일)피페리딘-1-카르복스아미드를 사용한 수축기 기능장애 및 감소된 박출 계수를 가진 심부전의 치료

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116082326A (zh) * 2022-12-16 2023-05-09 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
CN117865941A (zh) * 2024-03-13 2024-04-12 上海方予健康医药科技有限公司 取代哌啶化合物及其制备方法和应用

Also Published As

Publication number Publication date
MX2022000606A (es) 2022-03-11
JP2025148397A (ja) 2025-10-07
US20220289709A1 (en) 2022-09-15
US20210053939A1 (en) 2021-02-25
CL2022000050A1 (es) 2022-10-14
PE20220645A1 (es) 2022-04-28
IL289817A (en) 2022-03-01
EP3999504A1 (en) 2022-05-25
CA3143965A1 (en) 2021-01-21
TW202116765A (zh) 2021-05-01
AU2020315605A1 (en) 2022-03-03
KR20220035176A (ko) 2022-03-21
WO2021011586A1 (en) 2021-01-21
BR112022000474A2 (pt) 2022-05-17
CO2022000117A2 (es) 2022-01-17
JP2022540678A (ja) 2022-09-16
US12459919B2 (en) 2025-11-04

Similar Documents

Publication Publication Date Title
CN107428719B (zh) 用于治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物
JP6603213B2 (ja) 心臓状態に対するピリミジンジオン化合物
JP2025148397A (ja) （ｒ）－４－（１－（（３－（ジフルオロメチル）－１－メチル－１ｈ－ピラゾール－４－イル）スルホニル）－１－フルオロエチル）－ｎ－（イソキサゾール－３－イル）ピペリジン－１－カルボキシアミドの多形体
CN110698415B (zh) 一种肌球蛋白抑制剂及其制备方法和用途
JPS61130280A (ja) ピペリジン誘導体
TWI921306B (zh) (r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺醯基)-1-氟乙基)-n-(異噁唑-3-基)哌啶-1-甲醯胺之多晶型物形式
JP7359460B2 (ja) 心不整脈および心不全の処置のための化合物
US20260028332A1 (en) Polymorphic form of glp-1r agonist, preparation method therefor and use thereof
US7429679B2 (en) Sulphonic acid salt of sibutramine
EP2649996A1 (en) Crystalline forms of sartans like telmisartan with beta blockers
CN108069940A (zh) 硫代乙酸化合物、组合物及其应用
JPH08225513A (ja) ナフトイルグアニジン誘導体
EA052690B1 (ru) Полиморфные формы (r)-4-(1-((3-(дифторметил)-1-метил-1н-пиразол-4-ил)сульфонил)-1-фторэтил)-n-(изоксазол-3-ил)пиперидин-1-карбоксамида
US20250034129A1 (en) CRYSTALLINE FORMS OF (6S,7S)-6-FLUORO-7-(2-FLUORO-5-METHYLPHENYL)-3-(TETRAHYDRO-2H-PYRAN-4-YL)-5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINE-2,4(1H,3H)-DIONE
WO2025244956A1 (en) Methods of manufacturing danicamtiv
HK40027481A (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
JP2025525093A (ja) （６Ｓ，７Ｓ）－６－フルオロ－７－（２－フルオロ－５－メチルフェニル）－３－（テトラヒドロ－２Ｈ－ピラン－４－イル）－５，６，７，８－テトラヒドロピリド［２，３－ｄ］ピリミジン－２，４（１Ｈ，３Ｈ）－ジオン
JP2012532140A (ja) Ａ２ａｒ作動薬としてのアルコキシ−カルボニル−アミノ−アルキニル−アデノシン化合物及びその誘導体
HK40027481B (zh) 用於治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物
KR20030002304A (ko) 3-페닐-3,7-디아자비시클로[3.3.1]노난 화합물들과 이들의제조방법 및 이러한 화합물들을 포함하는 약제들
JP2025517714A (ja) トリアジンジオン系誘導体の結晶形及び調製方法
KR20250121602A (ko) 간질성 폐 질환을 치료하기 위한 lpa1 길항제
CN119039236A (zh) 一种苄胺嘧啶二酮衍生物及其用途
WO2019072130A1 (zh) 一种1,2,4-三氮唑类化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination